口服rilzabrutinib治疗寻常型天疱疮的II期BELIEVE概念验证研究
BELIEVE是一项多中心II期概念验证试验,纳入27例寻常型天疱疮患者,口服rilzabrutinib 400–600 mg每日两次治疗12周。主要终点为零至低剂量糖皮质激素下4周内疾病活动控制,14例(52%,95%CI 32–71)达到该终点。治疗相关不良事件多为轻度,提示BTK抑制可能是天疱疮有前景的治疗策略。
要点
- 52%的患者在零至低剂量激素下4周内达到疾病活动控制。
- 6例(22%)在24周内达到完全缓解,其中4例(15%)在12周内达到。
- 治疗相关不良事件多为1–2级,1例发生3级蜂窝织炎。
核心结论
- Rilzabrutinib单用或联合远低于常规剂量的糖皮质激素治疗寻常型天疱疮安全,且具有快速临床活性。
- BTK抑制可能是天疱疮有前景的治疗策略,支持进一步研究rilzabrutinib。
研究设计与样本
- 多中心、概念验证、II期试验,纳入27例寻常型天疱疮患者,疾病严重程度评分(PDAI)8–45。
- 患者接受12周口服rilzabrutinib 400–600 mg每日两次,随后12周随访。
主要发现
- 主要终点零至低剂量CS下4周内疾病活动控制(CDA)在14例(52%,95%CI 32–71)中达成,其中11例使用低剂量CS、3例未用CS。
- 6例(22%)在24周内达到完全缓解,其中4例(15%)在12周内达到。
- 治疗相关不良事件多为轻度(1级或2级),1例发生3级蜂窝织炎。
临床怎么用
- 对于寻常型天疱疮患者,rilzabrutinib可单用或联合低剂量糖皮质激素使用,可能有助于减少激素用量。
- 治疗期间需监测不良事件,包括感染(如蜂窝织炎)。
局限性
- 本研究为概念验证性II期试验,样本量较小(27例),无对照组。
- 随访时间较短(共24周),长期疗效和安全性需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bruton tyrosine kinase (BTK) inhibition targets B-cell and other non-T-cell immune cells implicated in the pathophysiology of pemphigus, an autoimmune disease driven by anti-desmoglein autoantibodies. Rilzabrutinib is a new reversible, covalent BTK inhibitor demonstrating preclinical efficacy as monotherapy in canine pemphigus foliaceus. OBJECTIVES: To evaluate the efficacy and safety of oral rilzabrutinib in patients with pemphigus vulgaris in a multicentre, proof-of-concept, phase II trial. METHODS: Patients with Pemphigus Disease Area Index severity scores 8-45 received 12 weeks of oral rilzabrutinib 400-600 mg twice daily and 12 weeks of follow-up. Patients initially received between 0 and ≤ 0·5 mg kg-1 prednisone-equivalent corticosteroid (CS; i.e. 'low dose'), tapered after control of disease activity (CDA; no new lesions, existing lesions healing). The primary endpoints were CDA within 4 weeks on zero-to-low-dose CS and safety. RESULTS: In total, 27 patients with pemphigus vulgaris were included: nine newly diagnosed (33%) and 18 relapsing (67%); 11 had moderate disease (41%) and 16 moderate to severe (59%). The primary endpoint, CDA, was achieved in 14 patients (52%, 95% confidence interval 32-71): 11 using low-dose CS and three using no CS. Over 12 weeks of treatment, mean CS doses reduced from 20·0 to 11·8 mg per day for newly diagnosed patients and from 10·3 to 7·8 mg per day for relapsing patients. Six patients (22%) achieved complete response by week 24, including four (15%) by week 12. Treatment-related adverse events were mostly mild (grade 1 or 2); one patient experienced grade 3 cellulitis. CONCLUSIONS: Rilzabrutinib alone, or with much lower CS doses than usual, was safe, with rapid clinical activity in pemphigus vulgaris. These data suggest that BTK inhibition may be a promising treatment strategy and support further investigation of rilzabrutinib for the treatment of pemphigus.
引用
- Murrell DF, Patsatsi A, Stavropoulos P, et al. Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study. Br J Dermatol. 2021. PMID: 33942286. doi:10.1111/bjd.20431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。